Pompe Disease - A Pipeline Analysis Report | Technavio
LONDON--(BUSINESS WIRE)--May 15, 2018-- has announced its latest pipeline analysis report on the . The report comprises an in-depth analysis of the pipeline molecules under investigation within the defined data collection period to treat Pompe disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180515005796/en/
Technavio has published a new pipeline analysis report on the global Pompe disease market, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Pompe disease - market overview
Pompe disease market is also known as type II glycogen storage disease or acid maltase deficiency disease. It is an autosomal recessive disorder caused by an accumulation of glycogen skeletal and cardiac muscle due to the deficiency of the lysosomal acid alpha-glucosidase enzyme. The glycogen accumulation impairs the ability of muscles to function normally. Pompe disease can also be life-threatening if breathing and heart muscles get affected.
According to a senior analyst at Technavio for research , “Pompe disease occurs due to GAA gene mutations. GAA gene is located on the 17thchromosome and it delivers instructions for alpha-glucosidase enzyme production. The age of disease onset and disease severity are related to the degree of alpha-glucosidase deficiency.”
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Pompe disease – market segmentation
This market research report segments the based on therapies employed (monotherapy, combination therapy, and unknown), therapeutic modalities (gene therapy, small molecule, and recombinant enzyme), and RoA (IV, oral, IV + oral, and unspecified).
The IV RoA is expected to account for around 63% of the market share. IV delivers liquid substances directly into the vein. In the current pipeline, ten molecules are for IV RoA. Base on therapies employed, monotherapy which involves the use of a single drug for treatment is expected to account for 69% of the market. In the current pipeline, 11 molecules are for monotherapy.
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180515005796/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH INFECTIOUS DISEASES RESEARCH SCIENCE
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 05/15/2018 07:32 AM/DISC: 05/15/2018 07:32 AM